129 related articles for article (PubMed ID: 18386260)
1. The potential role of purine-rich element binding protein (PUR) alpha as a novel treatment target for hormone-refractory prostate cancer.
Inoue T; Leman ES; Yeater DB; Getzenberg RH
Prostate; 2008 Jul; 68(10):1048-56. PubMed ID: 18386260
[TBL] [Abstract][Full Text] [Related]
2. Purine-rich element binding protein (PUR) alpha induces endoplasmic reticulum stress response, and cell differentiation pathways in prostate cancer cells.
Inoue T; Maeno A; Talbot C; Zeng Y; Yeater DB; Leman ES; Kulkarni P; Ogawa O; Getzenberg RH
Prostate; 2009 Jun; 69(8):861-73. PubMed ID: 19267365
[TBL] [Abstract][Full Text] [Related]
3. Androgen receptor overexpression in prostate cancer linked to Pur alpha loss from a novel repressor complex.
Wang LG; Johnson EM; Kinoshita Y; Babb JS; Buckley MT; Liebes LF; Melamed J; Liu XM; Kurek R; Ossowski L; Ferrari AC
Cancer Res; 2008 Apr; 68(8):2678-88. PubMed ID: 18413735
[TBL] [Abstract][Full Text] [Related]
4. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
[TBL] [Abstract][Full Text] [Related]
5. Identification of mu-crystallin as an androgen-regulated gene in human prostate cancer.
Malinowska K; Cavarretta IT; Susani M; Wrulich OA; Uberall F; Kenner L; Culig Z
Prostate; 2009 Jul; 69(10):1109-18. PubMed ID: 19353593
[TBL] [Abstract][Full Text] [Related]
6. PLZF regulates Pbx1 transcription and Pbx1-HoxC8 complex leads to androgen-independent prostate cancer proliferation.
Kikugawa T; Kinugasa Y; Shiraishi K; Nanba D; Nakashiro K; Tanji N; Yokoyama M; Higashiyama S
Prostate; 2006 Jul; 66(10):1092-9. PubMed ID: 16637071
[TBL] [Abstract][Full Text] [Related]
7. SOX9 is expressed in normal prostate basal cells and regulates androgen receptor expression in prostate cancer cells.
Wang H; McKnight NC; Zhang T; Lu ML; Balk SP; Yuan X
Cancer Res; 2007 Jan; 67(2):528-36. PubMed ID: 17234760
[TBL] [Abstract][Full Text] [Related]
8. Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development.
Ishiguro H; Nakaigawa N; Miyoshi Y; Fujinami K; Kubota Y; Uemura H
Prostate; 2005 Jun; 64(1):92-100. PubMed ID: 15666359
[TBL] [Abstract][Full Text] [Related]
9. Regulation of growth hormone receptors in human prostate cancer cell lines.
Bidosee M; Karry R; Weiss-Messer E; Barkey RJ
Mol Cell Endocrinol; 2009 Oct; 309(1-2):82-92. PubMed ID: 19540305
[TBL] [Abstract][Full Text] [Related]
10. Nkx3.1 and p27(KIP1) cooperate in proliferation inhibition and apoptosis induction in human androgen-independent prostate cancer cells.
Wang P; Ma Q; Luo J; Liu B; Tan F; Zhang Z; Chen Z
Cancer Invest; 2009 May; 27(4):369-75. PubMed ID: 19266349
[TBL] [Abstract][Full Text] [Related]
11. Human osteocalcin: a strong promoter for nitric oxide synthase gene therapy, with specificity for hormone refractory prostate cancer.
McCarthy HO; Coulter JA; Worthington J; Robson T; Hirst DG
J Gene Med; 2007 Jun; 9(6):511-20. PubMed ID: 17471586
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-4 stimulates androgen-independent growth in LNCaP human prostate cancer cells.
Lee SO; Pinder E; Chun JY; Lou W; Sun M; Gao AC
Prostate; 2008 Jan; 68(1):85-91. PubMed ID: 18008330
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
[TBL] [Abstract][Full Text] [Related]
14. Overexpression and gene amplification of BAG-1L in hormone-refractory prostate cancer.
Mäki HE; Saramäki OR; Shatkina L; Martikainen PM; Tammela TL; van Weerden WM; Vessella RL; Cato AC; Visakorpi T
J Pathol; 2007 Aug; 212(4):395-401. PubMed ID: 17503439
[TBL] [Abstract][Full Text] [Related]
15. Functional analysis of NKX3.1 in LNCaP prostate cancer cells by RNA interference.
Possner M; Heuser M; Kaulfuss S; Scharf JG; Schulz W; Hermann-Ringert R; Thelen P
Int J Oncol; 2008 Apr; 32(4):877-84. PubMed ID: 18360715
[TBL] [Abstract][Full Text] [Related]
16. Novel steroid receptor phyto-modulator compound a inhibits growth and survival of prostate cancer cells.
Yemelyanov A; Czwornog J; Gera L; Joshi S; Chatterton RT; Budunova I
Cancer Res; 2008 Jun; 68(12):4763-73. PubMed ID: 18559523
[TBL] [Abstract][Full Text] [Related]
17. Expression of a hyperactive androgen receptor leads to androgen-independent growth of prostate cancer cells.
Hsieh CL; Cai C; Giwa A; Bivins A; Chen SY; Sabry D; Govardhan K; Shemshedini L
J Mol Endocrinol; 2008 Jul; 41(1):13-23. PubMed ID: 18469090
[TBL] [Abstract][Full Text] [Related]
18. Expression of stress response protein Grp78 is associated with the development of castration-resistant prostate cancer.
Pootrakul L; Datar RH; Shi SR; Cai J; Hawes D; Groshen SG; Lee AS; Cote RJ
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):5987-93. PubMed ID: 17062670
[TBL] [Abstract][Full Text] [Related]
19. Differential phosphoprotein levels and pathway analysis identify the transition mechanism of LNCaP cells into androgen-independent cells.
Wang HQ; Yang B; Xu CL; Wang LH; Zhang YX; Xu B; Ji JT; Sun YH
Prostate; 2010 Apr; 70(5):508-17. PubMed ID: 19937597
[TBL] [Abstract][Full Text] [Related]
20. Isolation of a novel USF2 isoform: repressor of cathepsin B expression.
Yan S; Sloane BF
Gene; 2004 Aug; 337():199-206. PubMed ID: 15276216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
